RxDoctor Payments Data

Adnan Sammour, MD

Internal Medicine · Bradenton, FLNPI 1578560546

Payments from drug & device makers

$748in general payments, 2019–2025

Across 12 payments — averaging $62.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$237
  • Inspire Medical Systems, Inc.$142
  • Idorsia Pharmaceuticals US Inc$124
  • Abbott$69
  • Abiomed$60
  • Kowa Pharmaceuticals America, Inc.$38
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$748 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$406,919
Medicare patients
901
Services billed
8,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$207,928
OzempicSemaglutide59$69,449
XareltoRivaroxaban59$50,683
Tresiba Flextouch U-200Insulin Degludec17$33,712
JardianceEmpagliflozin30$32,183
MounjaroTirzepatide28$26,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,234
JanuviaSitagliptin Phosphate14$17,385
EntrestoSacubitril/Valsartan14$16,055
Rosuvastatin Calcium1,060$13,508
FarxigaDapagliflozin Propanediol22$11,934
Emgality PenGalcanezumab-Gnlm13$8,636
Levothyroxine Sodium598$6,138
SymbicortBudesonide/Formoterol Fumarate15$5,552
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$5,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$50,68359 claims
Lilly USA, LLCMounjaro$14$26,14728 claims
MerckJanuvia$11$17,38514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →